175213-46-4

Basic information

• Product Name: METHYL 1-BOC-4-PIPERIDINEACETATE
• Synonyms: N-BOC-4-PIPERIDINEACETIC ACID METHYL ESTER;METHYL 1-BOC-4-PIPERIDINEACETATE;t-Butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate;Methyl N-Boc-4-piperidineacetate Methyl 1-Boc-4-piperidineacetate 4-((Methoxycarbonyl)methyl)piperidine-1-carboxylic acid tert-butyl ester;tert-butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate;1-Boc-4-Piperidine acetate methyl ester;1-Boc-4-Piperidine acetic acid methyl ester;Methyl 1-N-Boc-4-piperidineacetate
• CAS NO: 175213-46-4
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.33
• Product Categories: Amines;blocks;Carboxes;pharmacetical
• Mol File: 175213-46-4.mol

Chemical Properties

• Boiling Point: 323.1 °C at 760 mmHg
• Flash Point: 149.2 °C
• Appearance: /
• Density: 1.062 g/cm³
• Vapor Pressure: 0.000267mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.88±0.40(Predicted)
• CAS DataBase Reference: METHYL 1-BOC-4-PIPERIDINEACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 1-BOC-4-PIPERIDINEACETATE(175213-46-4)
• EPA Substance Registry System: METHYL 1-BOC-4-PIPERIDINEACETATE(175213-46-4)

Safety Data

• Hazardous Substances Data: 175213-46-4(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C13H23NO4/c1-13(2,3)18-12(16)14-7-5-10(6-8-14)9-11(15)17-4/h10H,5-9H2,1-4H3

Upstream product

• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 169206-65-9 1-tert-butoxycarbonyl-4-[(methoxycarbonyl)methylene]piperidine 
• 7440-44-0 pyrographite 
• 7440-05-3 palladium 
• 865-33-8 potassium methanolate 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 67-56-1 methanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 168986-49-0 4-piperidine acetic acid methyl ester 
• 81270-37-3 methyl piperidine-4-acetate hydrochloride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 81270-37-3 methyl piperidine-4-acetate hydrochloride 
• 183170-69-6 1-tert-Butyloxycarbonyl-4-hydroxyethyl-piperidine 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 1103310-87-7 4-[3-(4-methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 865627-01-6 tert-butyl 4-(1-(3-fluoro-2-pivalamidophenyl)-1-hydroxy-3-methoxy-3-oxopropan-2-yl)piperidine-1-carboxylate 
• 1337918-84-9 4-[2-hydroxy-1-methoxycarbonyl-2-(2-nitro-phenyl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1352485-19-8 R,S-2-[4-(1H-indol-3-yl)-trans-cyclohexylamino]-2-[1-(trans-3,5-difluorocinnamoyl)piperidin-4-yl]-acetamide 
• 423722-27-4 2-(1-(methylsulfonyl)piperidin-4-yl)acetic acid 
• 881016-89-3 4-(bromo-carboxy-methyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 

Relevant articles and documents

Oxidative esterification of alcohols by a single-side organically decorated Anderson-type chrome-based catalyst

The direct esterification of alcohols with non-noble metal-based catalytic systems faces great challenges. Here, we report a new chrome-based catalyst stabilized by a single pentaerythritol decorated Anderson-type polyoxometalate, [N(C4H9)4]3[CrMo6O18(OH)3C{(OCH2)3CH2OH}], which can realize the efficient transformation from alcohols to esters by H2O2oxidation in good yields and high selectivity without extra organic ligands. A variety of alcohols with different functionalities including some natural products and pharmaceutical intermediates are tolerated in this system. The chrome-based catalyst can be recycled several times and still keep the original configuration and catalytic activity. We also propose a reasonable catalytic mechanism and prove the potential for industrial applications.

INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS

Provided is pharmaceutical composition for intranasal delivery, wherein the pharmaceutical composition includes a therapeutically active ingredient including a CGRP inhibitor. Also provided is a method for delivering a CGRP inhibitor to a subject, wherein

Conversion of alcohols to alkyl esters and carboxylic acids using heterogeneous palladium-based catalysts

Disclosed are methods for synthesizing an ester or a carboxylic acid from an organic alcohol. To form the ester one reacts, in the presence of oxygen gas, the alcohol with methanol or ethanol. This reaction occurs in the presence of a catalyst comprising palladium and a co-catalyst comprising bismuth, tellurium, lead, cerium, titanium, zinc and/or niobium (most preferably at least bismuth and tellurium). Alternatively that catalyst can be used to generate an acid from that alcohol, when water is also added to the reaction mix.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ( BTK ) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4- yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1- carboxamide (BMS-742413): A potent human CGRP antagonist with superior safety profile for the treatment of mi

Calcitonin gene-related peptide (CGRP) receptor antagonists have been shown to be efficacious as abortive migraine therapeutics with the absence of cardiovascular liabilities that are associated with triptans. Herein, we report the discovery of a highly p

Aerobic oxidation of diverse primary alcohols to methyl esters with a readily accessible heterogeneous Pd/Bi/Te catalyst

Efficient aerobic oxidative methyl esterification of primary alcohols has been achieved with a heterogeneous catalyst consisting of 1 mol % Pd/charcoal (5 wt %) in combination with bismuth(III) nitrate and tellurium metal. The Bi and Te additives significantly increase the reaction rate, selectivity, and overall product yields. This readily accessible catalyst system exhibits a broad substrate scope and is effective with both activated (benzylic) and unactivated (aliphatic) alcohols bearing diverse functional groups.

CGRP RECEPTOR ANTAGONIST

The disclosure generally relates to the compound of formula I, (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide, including pharmaceutically acceptable salts, which is a CGRP-receptor antagonist. The disclosure also relates to pharmaceutical compositions and methods for using the compound in the treatment of CGRP related disorders including migraine headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cancer.

FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.